Inverness Medical Innovations, Inc. (Inverness Medical), an in vitro diagnostics company, has elected Eli Y. Adashi to its board of directors. Adashi, a physician-scientist-executive with over 25 years of experience in Health Care and in the Life Sciences was also appointed to serve as a member of the board’s compensation committee.
A member of the Institute of Medicine of the National Academy of Sciences and its committees on Human Embryonic Stem Cell Research and on Women’s Health Research, Adashi is the founder and former leader of the multidisciplinary Ovarian Cancer Program of the NCI-designated Huntsman Cancer Research Institute. Adashi also served on sabbatical on the Quality Improvement Group of the Office of Clinical Standards and Quality, Centers for Medicare and Medicaid Services (CMS) and is a current ad hoc member of the Reproductive Health Drugs Advisory Committee of the U.S. Food & Drug Administration. A fellow of the American Association for the Advancement of Science and a member of the Association of American Physicians, Adashi is the author or co-author of over 250 peer-reviewed publications, over 120 book chapters/reviews, and 13 books focusing on ovarian biology, ovarian cancer and reproductive health.